Skip to main content
. Author manuscript; available in PMC: 2022 Jun 27.
Published in final edited form as: Clin Cancer Res. 2021 Jun 17;27(17):4757–4767. doi: 10.1158/1078-0432.CCR-21-0903

Table 3.

BOR.

Disease type
Best overall
response
Melanoma
(n = 12)
NSCLC
(n = 1)
RCC
(n = 13)
TOTAL
(n = 26)
Partial response
 Confirmed 0 0 0 0
 Unconfirmed 1 0 0 1
 Total PR 1 (4%)
Stable disease
 Confirmed 1 0 3 4
 Unconfirmed 2 1 1 4
 Total SD 8 (31%)
Progressive disease
 Confirmed 4 0 4 8
 Unconfirmed 3 0 5 8
 Total PD 16 (62%)
Unevaluable 1 0 0 1 (4%)